Quality of life and cancer-related needs in patients with choroidal melanoma.

TitleQuality of life and cancer-related needs in patients with choroidal melanoma.
Publication TypeJournal Article
Year of Publication2013
AuthorsWiley JF, Laird K, Beran T, McCannel TA, Stanton AL
JournalBr J Ophthalmol
Volume97
Issue11
Pagination1471-4
Date Published2013 Nov
ISSN1468-2079
KeywordsAdult, Aged, Aged, 80 and over, Choroid Neoplasms, Combined Modality Therapy, Female, Follow-Up Studies, Humans, Incidence, Los Angeles, Male, Melanoma, Middle Aged, Neoplasm Recurrence, Local, Quality of Life, Surveys and Questionnaires, Survival Rate, Treatment Outcome, Visual Acuity, Young Adult
Abstract

AIMS: To assess quality of life (QoL) indices and their associations with treatment modality, sociodemographics and cancer-related needs in choroidal melanoma patients.

METHODS: Patients (N=99) treated at the University of California, Los Angeles, for choroidal melanoma within the prior 5 years (M=2.05) completed questionnaires assessing demographics, cancer-related needs, vision-specific QoL, depressive symptoms and concern about recurrence. Visual acuity, comorbidities, treatment modality (radiotherapy, enucleation) and years since diagnosis were gathered from medical records. Primary analyses were multiple regressions.

RESULTS: Although concern about cancer recurrence was elevated, QoL was better than in other oncology samples and comparable with healthy samples on some outcomes. Enucleation was associated with worse vision-specific QoL, and presence of comorbid diseases was associated with worse vision-specific QoL, depressive symptoms and concern about cancer recurring (all p values<0.05). Patients who experienced at least one stressful life event in the past year (vs no events) reported more depressive symptoms (p<0.01). Report of more unmet cancer needs was associated with worse vision-specific QoL, depressive symptoms and more concern about recurrence (all p values<0.05), uniquely explaining 4%-12% of the variance.

CONCLUSIONS: For choroidal melanoma patients, an average of 2 years after treatment, the number of physical comorbidities and unmet cancer needs were the strongest correlates of poorer QoL.

DOI10.1136/bjophthalmol-2013-303635
Alternate JournalBr J Ophthalmol
PubMed ID24037609
PubMed Central IDPMC3838665
Grant ListT32 GM084903 / GM / NIGMS NIH HHS / United States
T32GM084903 / GM / NIGMS NIH HHS / United States